Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41598-017-19063-6
Title: Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge
Authors: De Camargo, T.M
De Freitas, E.O
Gimenez, A.M
Lima, L.C
De Almeida Caramico, K
Françoso, K.S
Bruna-Romero, O
Andolina, C
Nosten, F
Rénia, L 
Ertl, H.C.J
Nussenzweig, R.S
Nussenzweig, V
Rodrigues, M.M
Reyes-Sandoval, A
Soares, I.S
Keywords: circumsporozoite protein, Protozoan
immunoglobulin G
malaria vaccine
protozoal protein
protozoon antibody
recombinant protein
Adenoviridae
administration and dosage
amino acid sequence
animal
antibody affinity
blood
chemistry
disease model
female
gene vector
genetics
immunization
immunology
mortality
mouse
Plasmodium vivax
Plasmodium vivax malaria
vaccine immunogenicity
Adenoviridae
Amino Acid Sequence
Animals
Antibodies, Protozoan
Antibody Affinity
Disease Models, Animal
Female
Genetic Vectors
Immunization
Immunogenicity, Vaccine
Immunoglobulin G
Malaria Vaccines
Malaria, Vivax
Mice
Plasmodium vivax
Protozoan Proteins
Recombinant Proteins
Issue Date: 2018
Citation: De Camargo, T.M, De Freitas, E.O, Gimenez, A.M, Lima, L.C, De Almeida Caramico, K, Françoso, K.S, Bruna-Romero, O, Andolina, C, Nosten, F, Rénia, L, Ertl, H.C.J, Nussenzweig, R.S, Nussenzweig, V, Rodrigues, M.M, Reyes-Sandoval, A, Soares, I.S (2018). Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge. Scientific Reports 8 (1) : 1118. ScholarBank@NUS Repository. https://doi.org/10.1038/s41598-017-19063-6
Rights: Attribution 4.0 International
Abstract: Vaccine development against Plasmodium vivax malaria lags behind that for Plasmodium falciparum. To narrow this gap, we administered recombinant antigens based on P. vivax circumsporozoite protein (CSP) to mice. We expressed in Pichia pastoris two chimeric proteins by merging the three central repeat regions of different CSP alleles (VK210, VK247, and P. vivax-like). The first construct (yPvCSP-AllFL) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct (yPvCSP-AllCT) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific to all CSP alleles. After challenge with P. berghei ANKA transgenic parasites expressing Pb/PvVK210 or Pb/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. These vaccine formulations should be clinically tried for their potential as protective universal vaccine against P. vivax malaria. © 2018 The Author(s).
Source Title: Scientific Reports
URI: https://scholarbank.nus.edu.sg/handle/10635/177831
ISSN: 20452322
DOI: 10.1038/s41598-017-19063-6
Rights: Attribution 4.0 International
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_s41598-017-19063-6.pdf2.83 MBAdobe PDF

OPEN

NoneView/Download

SCOPUSTM   
Citations

14
checked on Feb 27, 2021

Page view(s)

32
checked on Mar 5, 2021

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons